PE20200402A1 - Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4de lipoxina (fpr2/alx) para el tratamiento de la insuficiencia cardiaca - Google Patents

Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4de lipoxina (fpr2/alx) para el tratamiento de la insuficiencia cardiaca

Info

Publication number
PE20200402A1
PE20200402A1 PE2019002437A PE2019002437A PE20200402A1 PE 20200402 A1 PE20200402 A1 PE 20200402A1 PE 2019002437 A PE2019002437 A PE 2019002437A PE 2019002437 A PE2019002437 A PE 2019002437A PE 20200402 A1 PE20200402 A1 PE 20200402A1
Authority
PE
Peru
Prior art keywords
receptor
fpr2
lipoxin
alx
agonist
Prior art date
Application number
PE2019002437A
Other languages
English (en)
Spanish (es)
Inventor
Jacek Ostrowski
Ricardo Garcia
Nicholas B Wurtz
Nancy Leigh Carson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62567841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20200402(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20200402A1 publication Critical patent/PE20200402A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2019002437A 2017-05-22 2018-05-22 Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4de lipoxina (fpr2/alx) para el tratamiento de la insuficiencia cardiaca PE20200402A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762509489P 2017-05-22 2017-05-22
PCT/US2018/033783 WO2018217684A1 (en) 2017-05-22 2018-05-22 Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure

Publications (1)

Publication Number Publication Date
PE20200402A1 true PE20200402A1 (es) 2020-02-26

Family

ID=62567841

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002437A PE20200402A1 (es) 2017-05-22 2018-05-22 Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4de lipoxina (fpr2/alx) para el tratamiento de la insuficiencia cardiaca

Country Status (15)

Country Link
US (1) US20200069644A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630097A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020520948A (cg-RX-API-DMAC7.html)
KR (1) KR20200006595A (cg-RX-API-DMAC7.html)
CN (1) CN110662538A (cg-RX-API-DMAC7.html)
AU (1) AU2018273382A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019024185A2 (cg-RX-API-DMAC7.html)
CA (1) CA3064291A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003325A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019013015A2 (cg-RX-API-DMAC7.html)
EA (1) EA201992704A1 (cg-RX-API-DMAC7.html)
IL (1) IL270749A (cg-RX-API-DMAC7.html)
MX (1) MX2019013926A (cg-RX-API-DMAC7.html)
PE (1) PE20200402A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018217684A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
EP4178946A1 (en) 2020-07-09 2023-05-17 Bristol-Myers Squibb Company Oxopyrrolidine fpr2 agonists
ES2986512T3 (es) 2020-07-09 2024-11-11 Bristol Myers Squibb Co Agonistas del receptor 2 del péptido formil pirazolona
WO2022035923A1 (en) 2020-08-12 2022-02-17 Bristol-Myers Squibb Company Oxopyrrolidine urea fpr2 agonists
WO2022076764A1 (en) * 2020-10-09 2022-04-14 Bristol-Myers Squibb Company Aminoimidazole fpr2 agonists
CN119055775A (zh) * 2022-07-30 2024-12-03 中国医学科学院阜外医院 Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途
CN118831080B (zh) * 2024-09-24 2024-11-22 上海交通大学医学院附属仁济医院 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536187A (ja) * 2002-04-03 2005-12-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト N−ホルミルペプチド受容体様1(fprl1)に関連する疾患の診断および治療
EP3305763B1 (en) * 2013-11-28 2019-07-24 Kyorin Pharmaceutical Co., Ltd. Deuterated or isotopically labeled urea derivatives or pharmacologically acceptable salts thereof useful as fprl-1 agonists
KR101645015B1 (ko) * 2014-03-11 2016-08-03 포항공과대학교 산학협력단 Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물

Also Published As

Publication number Publication date
AU2018273382A1 (en) 2020-01-16
IL270749A (en) 2020-01-30
EP3630097A1 (en) 2020-04-08
CL2019003325A1 (es) 2020-04-17
CO2019013015A2 (es) 2020-01-17
BR112019024185A2 (pt) 2020-06-02
MX2019013926A (es) 2020-01-20
WO2018217684A1 (en) 2018-11-29
CN110662538A (zh) 2020-01-07
KR20200006595A (ko) 2020-01-20
CA3064291A1 (en) 2018-11-29
US20200069644A1 (en) 2020-03-05
JP2020520948A (ja) 2020-07-16
EA201992704A1 (ru) 2020-03-19

Similar Documents

Publication Publication Date Title
MX2024005839A (es) Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos.
CL2019003924A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).
PE20220766A1 (es) Agonistas de receptor de melanocortina-4
CR20210061A (es) Composiciones farmacéuticas que comprenden meloxicam
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
CO2019013015A2 (es) Uso novedoso de un agonista del receptor 2 de formil péptido / receptor a4de lipoxina (fpr2 / alx) para el tratamiento de la insuficiencia cardíaca
MX2019003098A (es) Composicion farmaceutica.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CL2017003208A1 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
PA8586101A1 (es) Forma de administracion de ibuprofeno sodico
MX390536B (es) Composicion farmaceutica topica que comprende al menos amitriptilina para el tratamiento del dolor neuropatico periferico.
BRPI0807940B8 (pt) usos de ácido 3´-{n´-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-diidropirazol-4-ilideno]-hidrazino}-2´-hidroxibifenil-3-carboxílico e/ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de câncer e de uma síndrome pré-cancerosa e composição farmacêutica que compreende dito ácido
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
JOP20250173A1 (ar) مثبط بروتين أرجينين مثيل ترانسفيراز 5-مثيل ثيوأدينوزين
CO2017008426A2 (es) Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico
UY31826A (es) Compuesto peptídico y su uso
MX2021003030A (es) Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion.
CO2021010380A2 (es) Composiciones farmacéuticas que comprenden meloxicam
MX2025009680A (es) Agonista policíclico del receptor de la hormona tiroidea beta y uso del mismo
MX2022011651A (es) Composicion farmaceutica para tratamiento de diabetes.
FR3073398B1 (fr) Triterpenes pentacycliques dans le traitement d'une pathologie bucco-dentaire